ReviewJournal of diabetes research2020
The Impact of Antidiabetic Agents on Sarcopenia in Type 2 Diabetes: A Literature Review.
Review in Journal of diabetes research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 34 citations in OpenAlex.
- Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2023Trial
- Phase angle as an independent predictor of sarcopenia and glycemic control in older adults with type 2 diabetes: a cross-sectional observational study.Journal of diabetes and metabolic disorders · 2025Article
- Diabetic Sarcopenia. A proposed muscle screening protocol in people with diabetes : Expert document.Reviews in endocrine & metabolic disorders · 2024Review
- The Relationship between physical activity, nutritional status, and sarcopenia in community- dwelling older adults with type 2 diabetes: a cross-sectional study.BMC geriatrics · 2024Article
- Drug-related sarcopenia as a secondary sarcopenia.Geriatrics & gerontology international · 2024Review
- Age Is Just a Number: Progress and Obstacles in the Discovery of New Candidate Drugs for Sarcopenia.Cells · 2023Review
- The Bidirectional Relationship between Periodontal Disease and Diabetes Mellitus-A Review.Diagnostics (Basel, Switzerland) · 2023Review
- The Association Between Sarcopenia and Diabetes: From Pathophysiology Mechanism to Therapeutic Strategy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- The Promotion of Migration and Myogenic Differentiation in Skeletal Muscle Cells by Quercetin and Underlying Mechanisms.Nutrients · 2022Article
- Hepatogenous diabetes: Knowledge, evidence, and skepticism.World journal of hepatology · 2022Review
- Management of Type 2 Diabetes Mellitus in Elderly Patients with Frailty and/or Sarcopenia.International journal of environmental research and public health · 2022Review
- Gender Differences in Body Composition in Pre-Frail Older Adults With Diabetes Mellitus.Frontiers in endocrinology · 2022Article
- Anti-diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications.Journal of cachexia, sarcopenia and muscle · 2021Review
- Effects of Root Extract ofACS omega · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is a geriatric syndrome characterized by decline of skeletal muscle mass and function. Contributing factors include nutritional, genetic, inflammatory, and endocrinal factors. The reported prevalence of sarcopenia in type 2 diabetes mellitus is high, especially in patients with poor glycemic control. Additionally, antidiabetic agents may alter the balance between protein synthesis and degradation through various mechanisms of skeletal muscle mass regulation. This study reviewed the literature on the pathogenesis of sarcopenia in diabetes mellitus and the current understanding of whether antidiabetic agents contribute positively or negatively to sarcopenia and muscle wasting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.